KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Intangibles (2016 - 2024)

CRISPR Therapeutics AG's Intangibles history spans 10 years, with the latest figure at $2000.0 for Q1 2024.

  • For Q1 2024, Intangibles fell 96.49% year-over-year to $2000.0; the TTM value through Mar 2024 reached $2000.0, down 96.49%, while the annual FY2023 figure was $16000.0, 77.46% down from the prior year.
  • Intangibles for Q1 2024 was $2000.0 at CRISPR Therapeutics AG, down from $16000.0 in the prior quarter.
  • Across five years, Intangibles topped out at $221000.0 in Q1 2020 and bottomed at $2000.0 in Q1 2024.
  • The 5-year median for Intangibles is $112000.0 (2022), against an average of $111764.7.
  • The largest annual shift saw Intangibles fell 19.93% in 2020 before it tumbled 96.49% in 2024.
  • A 5-year view of Intangibles shows it stood at $180000.0 in 2020, then plummeted by 30.56% to $125000.0 in 2021, then crashed by 43.2% to $71000.0 in 2022, then crashed by 77.46% to $16000.0 in 2023, then tumbled by 87.5% to $2000.0 in 2024.
  • Per Business Quant, the three most recent readings for CRSP's Intangibles are $2000.0 (Q1 2024), $16000.0 (Q4 2023), and $30000.0 (Q3 2023).